UCB has announced plans to establish a major new biologics manufacturing facility in Gwinnett County, Georgia, marking a significant step in the company’s long-term U.S. expansion strategy. The state-of-the-art campus will be located within the Rowen development, a growing innovation district in the Atlanta metropolitan area.
The planned facility will span approximately 460,000 square feet—roughly equivalent to eight football fields—across a 79-acre site. Designed with a digital-first approach, the campus will integrate advanced technologies such as artificial intelligence, robotics, and automation while prioritizing efficient use of natural resources. Once operational, the site is expected to manufacture complex biologics around the clock, primarily serving the U.S. market.
This investment reinforces UCB’s commitment to strengthening its global biologics manufacturing network and improving supply chain resilience. The new facility will also support increasing demand for the company’s biologics portfolio and future pipeline, positioning it as a cornerstone of UCB’s global production capabilities.
According to CEO Jean-Christophe Tellier, the decision reflects confidence in the company’s sustained growth and its longstanding presence in the United States. UCB has maintained its U.S. headquarters in Georgia for more than three decades, and this expansion further deepens its ties to the region. Tellier highlighted the state’s skilled workforce, strong manufacturing heritage, and supportive innovation ecosystem as key factors in the decision.
The project is expected to generate approximately $5 billion in total economic impact, making it one of the largest investments in Georgia’s history. It will create around 330 permanent high-skilled jobs and more than 1,000 construction roles during the development phase.
Georgia Governor Brian Kemp welcomed the announcement, noting its importance for the state’s life sciences sector and its role in establishing Georgia as a leading hub for innovation and advanced manufacturing.
The Rowen site offers strategic advantages, including proximity to top academic institutions such as Georgia Institute of Technology and University of Georgia, providing access to a strong talent pipeline in science, engineering, and manufacturing.
UCB has demonstrated consistent scientific and commercial progress in recent years, achieving 15 FDA approvals or indication expansions, including nine within the past three years. The new facility will support the production of both recently approved treatments and future innovations, helping bring advanced therapies closer to patients across the United States.
With approximately 2,000 employees already based in the U.S., UCB sees this expansion as a key step in enhancing its end-to-end capabilities—from research and development to manufacturing and commercialization—while continuing to improve outcomes for patients with severe diseases.